Abstract:BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available. BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available.

Targeting Tissue Inhibitor Of Metalloproteinase 1/2 Using A Shrna Lentiviral System Offers A Novel Treatment Strategy Against Hepatic Fibrosis

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Effects of Antisense Tissue Imhibitor of Metalloproteinase-1 Expressing Plasmid on Porcine Serum-Induced Rat Liver Fibrosis

Modified Synthetic Sirna Targeting Tissue Inhibitor of Metalloproteinase‐2 Inhibits Hepatic Fibrogenesis in Rats

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Effect of Shrna-Mediated Silencing of CTGF and TIMP-1 on Mrna Expression of CTGF, TIMP-1, and PCI and Secretion of Extracellular Matrix in Rat Hepatic Stellate Cells

Transplantation of Mesenchymal Stem Cells Expressing TIMP-1-shRNA Improves Hepatic Fibrosis in CCl₄-treated Rats.

Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis

Inhibitory Effect of Bone Morphogenetic Protein-7 on Hepatic Fibrosis in Rats

Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice

Effects of Sirna Targeting ADAMTS2 Gene on Hepatic Stellate Cells

Effect of Interleukin-10 and Platelet-Derived Growth Factor on Expressions of Matrix Metalloproteinases-2 and Tissue Inhibitor of Metalloproteinases-1 in Rat Fibrotic Liver and Cultured Hepatic Stellate Cells

Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.

TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis

[Effect of Recombinant Human Augmenter of Liver Regeneration on Gene Expression of Tissue Inhibitor of Metalloproteinase-1 in Rat with Experimental Liver Fibrosis].

Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro.

Effects of Antisense Tissue Inhibitor Metalloproteinase -1 on Hepatic Stellate Cells

Recombinant Human Augmenter of Liver Regeneration Can Decrease Gene Expression of Tissue Inhibitor of Metalloproteinases-1 in Fibrotic Rats

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Effects of Matrix Metalloproteinase-1 and Antisense Tissue Inhibitor of Metalloproteinase-1 Recombinant Plasmid on Rat Liver Fibrosis

722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells